2022年8月18日,

Moximed,一個醫療設備公司的使命是提高護理標準的膝骨關節炎(OA)患者C係列宣布4000萬美元的股權和債務融資。圓是由出現生命科學和新企業協會還包括恢複投資者(NEA),未來基金,頂點醫療、Gilde醫療、GBS Venture Partners和morgenthal的企業,債務融資提供的跑道增長型資本。所得資金將用於獲得必要的批準和建立MISHA膝蓋的商業基礎設施係統,世界上第一個植入減震器(ISA)膝蓋。致力於幫助患有輕度到中度骨關節炎保護膝關節,積極生活,Moximed利用建立的臨床好處的重量減負荷係統病變關節設計MISHA膝蓋。植入在門診過程中,米莎膝蓋係統已經被證明可以減輕疼痛,改善功能,可能會推遲一些病人需要全膝關節置換。結果Moximed最近完成了海中女神的關鍵設備的研究將會在骨科峰會(OSET)在波士頓9月22日,2022年。“一旦疲憊的非手術治療,病人患有膝關節OA變得非常沮喪,缺乏選項來解決他們的持續疼痛和殘疾。作為外科醫生,我分享他們的挫敗感。時,盡管我們最好的醫療管理的努力,我的病人麵臨持久的慢性疼痛或提交早期關節置換,我離開給他們選擇,他們不想,”醫學博士Anil Ranawat說首席,髖關節和膝關節的運動醫學研究所特種外科醫院在紐約。骨關節炎(OA)是一種常見的、虛弱的條件,發展共同的自然減震器,軟骨和半月板,不再從日常活動,緩解關節導致慢性疼痛和活動限製。 Many people with mild to moderate OA are otherwise healthy, in their prime working years, and have busy lives to live. For these patients, total knee replacement is a reluctant option, as it is an end-stage treatment for end-stage disease. OA patients without end-stage disease seek options that preserve their knee, activity level, and quality of life. “We’ve listened carefully to patients, and their surgeons, and we’re excited to develop a solution that meets their needs,” said Anton Clifford, PhD, Moximed CEO. “Patients deserve treatment options that allow them to live life to their fullest abilities, whether it’s caring for a loved one, returning to a favorite sport, or simply getting through their working day. Results from our pivotal study show the MISHA Knee System not only alleviates pain and OA-induced activity limitations, but also offers complete preservation of the knee, an outpatient procedure, and early weight bearing. These are all strong preferences expressed by our patient population.” “Working people who have knee OA have been waiting for a solution that falls between conservative care and eventual joint replacement. Moximed has the potential to fill this gap in knee OA treatment with the MISHA Knee System, and we are excited to further support Moximed’s efforts to alter the treatment paradigm for millions of Americans,” said Shahzad Malik, MD, General Partner, Advent Life Sciences. [Source(s): Moximed, Business Wire]